A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2016
At a glance
- Drugs Agatolimod (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 20 Jun 2007 Pfizer has discontinued the PF-3512676 development programme because of no evidence of additional clinical efficacy compared with standard antineoplastics alone.
- 08 Aug 2006 Status change
- 14 Sep 2005 New trial record.